These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 660683)

  • 61. Drug dosing in patients with renal insufficiency. A simplified approach.
    Bakris GL; Talbert R
    Postgrad Med; 1993 Dec; 94(8):153-6, 159-60, 163-4. PubMed ID: 8247992
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Practical pharmacokinetic techniques for drug consultation and evaluation. IV: Gentamicin blood level versus time profiles of various dosage regimens recommended for renal impairment.
    Schumacher GE
    Am J Hosp Pharm; 1975 Mar; 32(3):299-308. PubMed ID: 1136979
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Practical pharmacokinetic techniques for drug consultation and evaluation. II. A perspective on the renal impaired patient.
    Schumacher GE
    Am J Hosp Pharm; 1973 Sep; 30(9):824-30. PubMed ID: 4582138
    [No Abstract]   [Full Text] [Related]  

  • 64. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
    Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evaluation of medication dosing errors in elderly patients with renal impairment
.
    Won HJ; Chung G; Lee KJ; Lee E; Son S; Choi S; Park SC; Lee YJ
    Int J Clin Pharmacol Ther; 2018 Aug; 56(8):358-365. PubMed ID: 29882509
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Functional range of creatinine clearance for renal drug dosing: a practical solution to the controversy of which weight to use in the Cockcroft-Gault equation.
    Brown DL; Masselink AJ; Lalla CD
    Ann Pharmacother; 2013; 47(7-8):1039-44. PubMed ID: 23757387
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Potentially inappropriate prescribing of renally cleared drugs in elderly patients in community and aged care settings.
    Khanal A; Peterson GM; Castelino RL; Jose MD
    Drugs Aging; 2015 May; 32(5):391-400. PubMed ID: 25925940
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impact of a renal drug dosing service on dose adjustment in hospitalized patients with chronic kidney disease.
    Hassan Y; Al-Ramahi RJ; Aziz NA; Ghazali R
    Ann Pharmacother; 2009 Oct; 43(10):1598-605. PubMed ID: 19776297
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prevalence of renally inappropriate medicines in older people with renal impairment - A cross-sectional register-based study in a large primary care population.
    Schmidt-Mende K; Wettermark B; Andersen M; Elsevier M; Carrero JJ; Shemeikka T; Hasselström J
    Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):256-265. PubMed ID: 30328682
    [TBL] [Abstract][Full Text] [Related]  

  • 70. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures.
    Pea F; Porreca L; Baraldo M; Furlanut M
    J Antimicrob Chemother; 2000 Mar; 45(3):329-35. PubMed ID: 10702552
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Amikacin serum concentrations: prediction of levels and dosage guidelines.
    Sarubbi FA; Hull JH
    Ann Intern Med; 1978 Nov; 89(5 Pt 1):612-8. PubMed ID: 717929
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Should estimates of glomerular filtration rate and creatinine clearance be indexed to body surface area for drug dosing?
    Nix DE; Mayersohn M; Erstad BL
    Am J Health Syst Pharm; 2017 Nov; 74(21):1814-1819. PubMed ID: 28947625
    [No Abstract]   [Full Text] [Related]  

  • 73. Appropriate dosing in patients with impaired renal function on medical wards before and after an educational intervention.
    Baum S; Harder S
    Int J Clin Pharmacol Ther; 2010 Jan; 48(1):29-35. PubMed ID: 20040337
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
    Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
    J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Calculation of drug dosage regimens in patients with renal disease: a new nomographic method.
    Spring P
    Int J Clin Pharmacol Biopharm; 1975 Jan; 11(1):76-80. PubMed ID: 1150365
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.
    Zhang L; Xu N; Xiao S; Arya V; Zhao P; Lesko LJ; Huang SM
    J Clin Pharmacol; 2012 Jan; 52(1 Suppl):79S-90S. PubMed ID: 22232757
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study.
    Aggarwal R; Dewan A
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):15. PubMed ID: 29571295
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.
    Xu H; Zhou W; Zhou D; Li J; Al-Huniti N
    J Clin Pharmacol; 2017 Mar; 57(3):336-344. PubMed ID: 27530649
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Pitfalls in the interpretation of laboratory parameters-electrolytes, urea, creatinine].
    Risch L; Hess B
    Ther Umsch; 2013 Aug; 70(8):457-64. PubMed ID: 23876752
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Suboptimal antimicrobial drug exposure in patients with renal impairment.
    Czock D; Spitaletta M; Keller F
    Int J Clin Pharm; 2015 Oct; 37(5):906-16. PubMed ID: 26017400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.